Cargando…

Renal allograft DARCness in subclinical acute and chronic active ABMR

Gene expression profiling of renal allograft biopsies revealed the Duffy antigen receptor for chemokines (DARC) as being strikingly upregulated in antibody‐mediated rejection (ABMR). DARC has previously been shown to be associated with endothelial injury. This study aimed at assessing the value of D...

Descripción completa

Detalles Bibliográficos
Autores principales: Kläger, Johannes, Eskandary, Farsad, Böhmig, Georg A., Kozakowski, Nicolas, Kainz, Alexander, Colin Aronovicz, Yves, Cartron, Jean‐Pierre, Segerer, Stephan, Regele, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453966/
https://www.ncbi.nlm.nih.gov/pubmed/33983671
http://dx.doi.org/10.1111/tri.13904
_version_ 1784570391181656064
author Kläger, Johannes
Eskandary, Farsad
Böhmig, Georg A.
Kozakowski, Nicolas
Kainz, Alexander
Colin Aronovicz, Yves
Cartron, Jean‐Pierre
Segerer, Stephan
Regele, Heinz
author_facet Kläger, Johannes
Eskandary, Farsad
Böhmig, Georg A.
Kozakowski, Nicolas
Kainz, Alexander
Colin Aronovicz, Yves
Cartron, Jean‐Pierre
Segerer, Stephan
Regele, Heinz
author_sort Kläger, Johannes
collection PubMed
description Gene expression profiling of renal allograft biopsies revealed the Duffy antigen receptor for chemokines (DARC) as being strikingly upregulated in antibody‐mediated rejection (ABMR). DARC has previously been shown to be associated with endothelial injury. This study aimed at assessing the value of DARC immunohistochemistry as diagnostic marker in ABMR. The study was performed on 82 prospectively collected biopsies of a clinically well‐defined population (BORTEJECT trial, NCT01873157) of DSA‐positive patients with gene expression data available for all biopsies. Diagnostic histologic assessment of biopsies was performed according to the Banff diagnostic scheme. DARC expression was focally accentuated, on peritubular capillaries (PTC) mostly in areas of interstitial fibrosis and/or inflammation. DARC positivity was associated with diagnosis of ABMR and correlated with DARC gene expression levels detected by microarray analysis. Still, as previously described, a substantial number of biopsies without signs of rejection showed DARC‐positive PTC. We did not observe significantly reduced graft survival in cases showing histologic signs of ABMR and being DARC‐positive, as compared to DARC‐negative ABMR. In summary, the upregulation of DARC, detected by immunohistochemistry, is associated with but not specific for ABMR. We did not observe reduced graft survival in DARC‐positive patients.
format Online
Article
Text
id pubmed-8453966
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84539662021-09-27 Renal allograft DARCness in subclinical acute and chronic active ABMR Kläger, Johannes Eskandary, Farsad Böhmig, Georg A. Kozakowski, Nicolas Kainz, Alexander Colin Aronovicz, Yves Cartron, Jean‐Pierre Segerer, Stephan Regele, Heinz Transpl Int Clinical Science Gene expression profiling of renal allograft biopsies revealed the Duffy antigen receptor for chemokines (DARC) as being strikingly upregulated in antibody‐mediated rejection (ABMR). DARC has previously been shown to be associated with endothelial injury. This study aimed at assessing the value of DARC immunohistochemistry as diagnostic marker in ABMR. The study was performed on 82 prospectively collected biopsies of a clinically well‐defined population (BORTEJECT trial, NCT01873157) of DSA‐positive patients with gene expression data available for all biopsies. Diagnostic histologic assessment of biopsies was performed according to the Banff diagnostic scheme. DARC expression was focally accentuated, on peritubular capillaries (PTC) mostly in areas of interstitial fibrosis and/or inflammation. DARC positivity was associated with diagnosis of ABMR and correlated with DARC gene expression levels detected by microarray analysis. Still, as previously described, a substantial number of biopsies without signs of rejection showed DARC‐positive PTC. We did not observe significantly reduced graft survival in cases showing histologic signs of ABMR and being DARC‐positive, as compared to DARC‐negative ABMR. In summary, the upregulation of DARC, detected by immunohistochemistry, is associated with but not specific for ABMR. We did not observe reduced graft survival in DARC‐positive patients. John Wiley and Sons Inc. 2021-06-25 2021-08 /pmc/articles/PMC8453966/ /pubmed/33983671 http://dx.doi.org/10.1111/tri.13904 Text en © 2021 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Clinical Science
Kläger, Johannes
Eskandary, Farsad
Böhmig, Georg A.
Kozakowski, Nicolas
Kainz, Alexander
Colin Aronovicz, Yves
Cartron, Jean‐Pierre
Segerer, Stephan
Regele, Heinz
Renal allograft DARCness in subclinical acute and chronic active ABMR
title Renal allograft DARCness in subclinical acute and chronic active ABMR
title_full Renal allograft DARCness in subclinical acute and chronic active ABMR
title_fullStr Renal allograft DARCness in subclinical acute and chronic active ABMR
title_full_unstemmed Renal allograft DARCness in subclinical acute and chronic active ABMR
title_short Renal allograft DARCness in subclinical acute and chronic active ABMR
title_sort renal allograft darcness in subclinical acute and chronic active abmr
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453966/
https://www.ncbi.nlm.nih.gov/pubmed/33983671
http://dx.doi.org/10.1111/tri.13904
work_keys_str_mv AT klagerjohannes renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT eskandaryfarsad renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT bohmiggeorga renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT kozakowskinicolas renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT kainzalexander renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT colinaronoviczyves renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT cartronjeanpierre renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT segererstephan renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr
AT regeleheinz renalallograftdarcnessinsubclinicalacuteandchronicactiveabmr